Awazi F.C.T

linezolid 600mg.

Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (penicillin-susceptible strains only).

Combination therapy may be clinically indicated if the documented or presumptive pathogens include gram-negative organisms .

-Complicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible and – resistant strains) , Streptococcus pyogenes, or Streptococcus agalactiae.

LINEZOLID has not been studied in the treatment of diabetic foot and decubitus ulcers.

Combination therapy may be clinically indicated if the documented or

presumptive pathogens include gram-negative organisms

-Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes.

-Community-acquired pneumonia caused by Streptococcus pneumoniae (penicillin-susceptible strains only), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only).

Due to concerns about inappropriate use of antibiotics leading to an increase in resistant organisms, prescribers should carefully consider alternatives before initiating treatment with LINEZOLID in the outpatient setting.

Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to linezolid. Therapy may be instituted empirically while awaiting the results of these tests

Once these results become available, antimicrobial therapy should be adjusted accordingly